coVita™ and Allergy Partners team up to improve asthma care in America

MAIDSTONE, U.K. - EntSun -- coVita™ LLC, a leader in advanced breath analysis and diagnostic solutions, serves as the U.S. distributor for the innovative NObreath^® Fractional Exhaled Nitric Oxide (FeNO) device from UK-based Bedfont^® Scientific Ltd. The new agreement with Allergy Partners marks the culmination of a strategic partnership developed over the past two years.

"The partnership established between coVita™ and Allergy Partners marks important progress in broadening access to FeNO technology on a global scale." Said Jason Smith, CEO at Bedfont^®. "We are pleased to support this collaboration and proud of the role coVita™ is playing in advancing high-quality asthma care."

As the nation's largest and most trusted integrated network of allergy and asthma specialists, Allergy Partners serves patients through more than 125 locations in over 20 states. Under the new agreement, all Allergy Partners clinics will provide FeNO testing with the NObreath^® device, enhancing patient access to advanced, non-invasive tools that aid in asthma diagnosis and management. The NObreath^® is the allergist's device of choice in the USA, further underscoring its value in supporting accurate assessment and personalised treatment. With 26.8 million Americans, 8.2% of the U.S. population, affected by asthma in 2022, the need for innovative tools to support better care and disease management has never been greater.

More on EntSun News

• A High-Velocity Growth Story Emerges in Marine and Luxury Markets
• $26 Billion Global Market by 2035 for Digital Assets Opens Major Potential for Currency Tech Company with ATM Expansion and Deployment Plans Underway
• Fashion in the feed: How social fashion platforms turn inspiration into purchases
• Elklook Launches The "Magnetic Glasses Toppers" Collection
• Peernovation 365 is Now Available

"We are incredibly proud of our collaboration with Allergy Partners and thrilled to help them implement the NObreath^® FeNO technology", said Jason Aversano, CEO at coVita™.  "Their determination to integrate FeNO testing across their entire network of providers is illustrative of their understanding of the vital role objective FeNO monitoring plays in the modern clinical setting."

Bedfont^® Scientific, manufacturer of the NObreath^®, and coVita™, share a long-standing partnership grounded in mutual respect, trust, and a shared vision to improve respiratory health through innovation. Over the years, the two companies have worked hand in hand to make advanced breath analysis more accessible to clinicians and patients throughout the United States. Their collaboration continues to exemplify how aligned values and global cooperation can drive meaningful change in healthcare.

To learn more about the NObreath^® FeNO device, visit the website here (https://www.nobreathfeno.com/).

More on EntSun News

• Sam's OATH Music Releases "Joy Anyway," a Song for Finding Joy While Living With Grief
• ITSE Magazine and In The Spirit Entertainment Record Label Launch Featuring Comedy Shucky Duckey
• Snap-a-Box Brings Texas' First Robot-Cooked Chinese Takeout to Katy–Fulshear
• UK Financial Ltd Makes History as MayaCat (SMCAT) Becomes the World's First Exchange-Traded ERC-3643 Security Token
• Narcissist Apocalypse Marks 7 Years as a Leading Narcissistic Abuse Podcast

References

1.       CDC. Most Recent Asthma Data [Internet]. Asthma Data. 2024. Available from: https://www.cdc.gov/asthma-data/about/most-recent-asthma-data.html